Calico

Calico (Calico Life Sciences LLC) is a pioneering, research-driven biotechnology company singularly focused on deciphering the biology of aging and translating those insights into novel therapeutics. Founded by Arthur D. Levinson and backed by Alphabet, it operates with a unique, long-term horizon, blending academic-style basic research in model organisms with industrial-scale drug discovery and development. Its pipeline includes several early- and clinical-stage assets targeting specific diseases of aging, supported by a robust technology platform and strategic collaborations with leading academic and industry partners.

An integrated, interdisciplinary platform combining deep basic research in model organisms (yeast, worms, mice) with advanced computational biology, data science, and proprietary technology invention (e.g., PERISCOPE) to decipher the biology of aging and identify therapeutic targets.

Calico operates in a nascent but rapidly evolving field of longevity biotech. It faces competition from other well-funded private companies (e.g., Altos Labs, Unity Biotechnology) and academic consortia also targeting aging mechanisms. Its unique advantages are its long-term Alphabet funding, hybrid research model, and strong leadership. For specific disease programs (e.g., ADPKD), it competes with other biopharma companies developing novel therapies.